Document:

License Agreement

 Exhibit 10.13 
  
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested 
 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 230.406 
  
 LICENSE AGREEMENT 
  
 This License Agreement (“Agreement”) is entered into effective as of this 31st day of August, 2000 (“Effective Date”), by and between Cryogen, Inc., a California corporation
(“Cryogen”), and CryoCor, Inc., a Delaware corporation (“CryoCor”). 
  
 WITNESSETH 
  
 WHEREAS, Cryogen is willing to grant a license to CryoCor with respect to certain of its intellectual property rights and CryoCor is willing to grant licenses to Cryogen with respect to certain enhancements thereof; 
  
 WHEREAS, it is a condition to the closing of the transactions contemplated by
that certain Contribution Agreement of even date herewith between the parties hereto (the “Contribution Agreement”) that the parties hereto enter into this Agreement. 
  
 NOW THEREFORE 
  
 In view of the foregoing premises and the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of
this is hereby acknowledged, the parties hereto hereby agree as follows: 
  
 1. DEFINITIONS 
  
 1.1
“Affiliate” means a corporation, company, or other legal entity now or hereinafter controlling, controlled by or under common control with a party hereto, for so long as such ownership or control exists. For the purposes of this
definition, control shall refer to a greater than 50% interest in the right to make decisions for such entity (e.g., greater than 50% ownership of the voting shares or other voting securities of such entity). Notwithstanding anything to the contrary
contained herein, “Affiliate” shall not include (i) in the case of Cryogen, CryoCor and (ii) in the case of CryoCor, Cryogen. 
  
 1.2 “Assigned Assets and Clinical Development Products” shall mean the assets and clinical development products assigned to CryoCor by
Cryogen pursuant to Section 1.2(a)(i) of the Contribution Agreement. 
  
 1.3 “CryoCor Enhancements” means any and all modifications, improvements and enhancements to the Cryogen Intellectual Property Rights, Licensed Products and Assigned Assets and Clinical Development Products made or
developed by or on behalf of CryoCor that may be used or useful in the Cryogen Fields and which have been reduced to a form of Written Idea Memorandum on or before [...***...]; provided, however, “CryoCor Enhancements” shall not
include such modifications, improvements and enhancements to the Cryogen Intellectual Property Rights, made or developed solely by Cryogen (or its employees) on behalf of CryoCor pursuant to the R&D Agreement. 
  
 1.4 “CryoCor Field” means cardiac or vascular
ablation to treat cardiac arrhythmias. 
  

					
	 	 	1.	 	* Confidential Treatment Requested

 1.5 “CryoCor Joint Enhancement Interest” means CryoCor’s undivided ownership
interest in a Joint Enhancement. 
  
 1.6 “Cryogen
Enhancements” means any and all modifications, improvements and enhancements to the Cryogen Intellectual Property Rights or to Licensed Products made or developed by or on behalf of Cryogen that may be used or useful in the CryoCor Field or
in connection with any of the Licensed Products and which have been reduced to a form of Written Idea Memorandum on or before [...***...]. Without limiting the generality of the foregoing, “Cryogen Enhancements” shall include such
modifications, improvements and enhancements to the Cryogen Intellectual Property Rights made or developed solely by Cryogen (or its employees) on behalf of CryoCor pursuant to the R&D Agreement. 
  
 1.7 “Cryogen Exclusive Field” means the field of gynecologic
ablatron or ablation of female reproductive organs and breasts. 
  
 1.8 “Cryogen Fields” means the Cryogen Exclusive Field and the Cryogen Nonexclusive Field. 
  
 1.9 “Cryogen Intellectual Property Rights” means the intellectual property rights owned by Cryogen used or useful in the CryoCor Field,
as particularly set forth and described in Exhibit A hereto. 
  
 1.10 “Cryogen Joint Enhancement Interest” means Cryogen’s undivided ownership interest in a Joint Enhancement. 
  
 1.11 “Cryogen Nonexclusive Field” means any and all fields of use other than the CryoCor Field and the Cryogen Exclusive Field.

  
 1.12 “Damages” shall have the meaning set
forth in Section 7.2(a) hereof. 
  
 1.13 “Joint
Enhancements” means any and all modifications, improvements and enhancements to the Cryogen Intellectual Property Rights, the Licensed Products or the Assigned Assets and Clinical Development Products, jointly made or jointly developed by
Cryogen and CryoCor that may be used or useful in the CryoCor Field, the Cryogen Fields or in connection with any of the Licensed Products and which have been reduced to a form of Written Idea Memorandum on or before [...***...]. 

 
 1.14 “Licensed Products” means any and all devices and
methods conceived, developed, manufactured, distributed or sold by CryoCor which utilize all or any portion of the Cryogen Intellectual Property Rights, Cryogen Enhancements or Joint Enhancements for use in performing cardiac or vascular ablation to
treat cardiac arrhythmias. 
  
 1.15 “NIST” means
the National Institute of Standards and Technology. 
  
 1.16
“NIST License Agreement” means that certain Exclusive License Agreement effective as of June 27, 1997 between NIST and Cryogen. 
  

					
	 	 	2.	 	* Confidential Treatment Requested

 1.17 “Other Enhancements” means any and all modifications, improvements and enhancements
to the Cryogen Intellectual Property Rights and/or the Licensed Products which are not CryoCor Enhancements, Cryogen Enhancements or Joint Enhancements. 
  
 1.18 “R&D Agreement” means the Research and Development Agreement of even date herewith between Cryogen and CryoCor. 
  
 1.19 “Written Idea Memorandum” means a written memorandum
prepared by Cryogen, CryoCor or jointly by Cryogen and CryoCor, as the case may be, which sets forth in reasonable detail a description of and the planned and potential uses with respect to a Cryogen Enhancement, CryoCor Enhancement or Joint
Enhancement, as the case may be. 
  
 2. LICENSE GRANTS 
  
 2.1 Exclusive License Grant to CryoCor. Cryogen hereby grants to
CryoCor and its Affiliates an exclusive, irrevocable, perpetual, worldwide, non-transferable (except in accordance with Section 8.2 hereof), royalty-free, fully-paid up license, with the right to sublicense, to make, have made, import, use,
have used, offer to sell, sell or have sold Licensed Products and perform and have performed processes under the Cryogen Intellectual Property Rights, the Cryogen Enhancements and the Cryogen Joint Enhancement Interest, solely in the CryoCor Field.

  
 2.2 Non-Exclusive License Grant to Cryogen. CryoCor
hereby grants to Cryogen and its Affiliates a nonexclusive, irrevocable, perpetual, worldwide, non-transferable (except in accordance with Section 8.2 hereof), royalty-free, fully-paid up license, with the right to sublicense, to make, have
made, import, use, have used, offer to sell, sell or have sold products (other than Licensed Products) and perform and have performed processes under the CryoCor Enhancements and the CryoCor Joint Enhancement Interest, solely in the Cryogen
Nonexclusive Field. 
  
 2.3 Exclusive License Grant to
Cryogen. CryoCor hereby grants to Cryogen and its Affiliates an exclusive, irrevocable, perpetual, worldwide, non-transferable (except in accordance with Section 8.2 hereof), royalty-free, fully-paid up license, with the right to
sublicense, to make, have made, import, use, have used, offer to sell, sell or have sold products (other than Licensed Products) and perform and have performed processes under the CryoCor Enhancements and the CryoCor Joint Enhancement interest,
solely in the Cryogen Exclusive Field. 
  
 2.4 Other
Enhancements. Any and all Other Enhancements shall be the sole and exclusive property of the party hereto that makes or discovers any such Other Enhancement and any such Other Enhancement shall not be subject to the licenses granted hereunder by
either Cryogen (pursuant to Section 2.1 hereof) or CryoCor (pursuant to Sections 2.2 or 2.3 hereof). 
  
 2.5 Sublicense of NIST License Agreement. Promptly after CryoCor’s written request, which request shall be received by Cryogen within ninety
(90) days after the date hereof, if at all, Cryogen shall request approval of NIST for an exclusive sublicense to CryoCor for the CryoCor Field of Cryogen’s rights under the NIST License. Cryogen and CryoCor agree that any such sublicense to
CryoCor shall be on substantially the same terms as the license granted 
  

 3. 

 under the NIST License Agreement to Cryogen by NIST as then in effect and such other terms as Cryogen and CryoCor shall
mutually agree in good faith. Notwithstanding the foregoing, Cryogen and CryoCor agree that the terms of any such sublicense shall provide that each of CryoCor and Cryogen shall be responsible for a [...***...] provided in the NIST License
Agreement. 
  
 3. PROSECUTION, MAINTENANCE AND ENFORCEMENT WITH RESPECT TO
CRYOGEN INTELLECTUAL PROPERTY RIGHTS 
  
 3.1 Prosecution
of Patent Applications. Cryogen agrees to use commercially reasonable efforts to maintain and enforce all issued patents included in the Cryogen Intellectual Property Rights (each a “Covered Cryogen Issued Patent”) and to use
commercially reasonable efforts to prosecute all patent applications included in the Cryogen Intellectual Property Rights or the Cryogen Enhancements (each a “Covered Cryogen Patent Application”), all at the sole cost and expense of
Cryogen. The drafting, filing, and prosecution of any Covered Cryogen Patent Application shall be Cryogen’s responsibility and shall be carried out by it in its reasonable discretion, subject to an obligation on the part of Cryogen to keep
CryoCor reasonably informed of all material developments with respect to the foregoing activities. Without limiting the generality of the foregoing, Cryogen shall provide to CryoCor reasonable opportunity to advise Cryogen in the prosecution, filing
and maintenance of the Covered Cryogen Issued Patents and the Covered Cryogen Patent Applications and Cryogen shall implement CryoCor’s requests if and to the extent that such requests are feasible, reasonable and not in conflict with the
policies and objectives of Cryogen as determined by Cryogen; provided, however, CryoCor shall be solely responsible for any and all fees, costs and expenses incurred by Cryogen with respect to the implementation of any such requests by CryoCor.
Notwithstanding the foregoing, if Cryogen determines that it no longer desires to prosecute a Covered Cryogen Patent Application or maintain a Covered Cryogen Issued Patent, it shall, by giving CryoCor corresponding notice in writing, offer to
CryoCor the assignment of its right, title and interest in such Covered Cryogen Patent Application or Covered Cryogen Issued Patent, as the case may be. If CryoCor accepts such offer within sixty (60) days after Cryogen gives such notice, Cryogen
shall assign to CryoCor all of Cryogen’s right, title and interest in such Covered Cryogen Patent Application or Covered Cryogen Issued Patent (subject to an irrevocable, perpetual, royalty-free, exclusive, unrestricted, sublicensable,
worldwide license in favor of Cryogen for applications other than Licensed Products), at no charge to CryoCor. Following any such assignment, CryoCor may draft, file, maintain, prosecute and defend such assigned Covered Cryogen Patent Application or
Covered Cryogen Issued Patent, as the case may be, in it sole discretion. Pending receipt of a response from CryoCor as to whether CryoCor will accept such offer or, if later, the expiration of sixty (60) day period, Cryogen shall use reasonable
efforts to extend any deadlines or take such action as may be reasonably required to prevent the abandonment of any such Covered Cryogen Patent Application or forfeiture of any such Covered Cryogen Issued Patent. 
  
 3.2 Infringement by Third Parties. 
  
 (a) CryoCor will promptly notify Cryogen in writing of any apparent
infringement, misappropriation or other wrongful exploitation of the Cryogen Intellectual Property Rights or Cryogen Enhancements by a third party, including, without limitation, infringement, misappropriation or other wrongful exploitation in the
field of using, making, selling, importing or otherwise commercially exploiting Licensed Products in the CryoCor Field. 
  

					
	 	 	4.	 	* Confidential Treatment Requested

 (i) Cryogen shall have the initial right, at its sole cost and expense, to determine whether to
bring suit to enjoin such infringement, misappropriation or wrongful exploitation and recover damages therefor. Cryogen will bring such action in its name, at its sole cost and expense, and will take such other action, at its sole cost and expense
in connection with the prosecution of such action. Any damages recovered in such action will be payable to Cryogen for its exclusive benefit. 
  
 (ii) If Cryogen does not bring any such action as provided in Section 3.2(a)(i) above, within [...***...] after written notice of
infringement, misappropriation or wrongful exploitation is given by CryoCor, CryoCor may cause Cryogen, at CryoCor’s sole cost and expense to bring suit in Cryogen’s name or Cryogen’s and CryoCor’s names to enjoin such
infringement, misappropriation or wrongful exploitation and recover damages therefor (the “Total Damages”), which shall be for CryoCor’s sole account to the extent the damages are attributable to use and exploitation of the
Cryogen Intellectual Property Rights or Cryogen Enhancements within the CryoCor Field (the “CryoCor Damages”) and shall be for the account of Cryogen to the extent the damages are attributable to use and exploitation of the Cryogen
Intellectual Property Rights or Cryogen Enhancements outside of the CryoCor Field (the “Cryogen Damages”) upon Cryogen’s reimbursement to CryoCor of Cryogen’s proportionate share of the costs and expenses of such action
equal to the Cryogen Damages divided by the Total Damages. 
  
 (b) In any action brought by Cryogen pursuant to either Section 3.2(a)(i) or Section 3.2(a)(ii) hereof, Cryogen shall select and control counsel for the prosecution of such suit. Cryogen agrees to keep CryoCor
reasonably informed of any and all material developments with respect to any such action or suit, all at the sole cost and expense of CryoCor, and shall give CryoCor the opportunity to review in advance all major decisions, positions or actions that
Cryogen wishes to take in any such action or suit which would impair any interest of CryoCor in the Cryogen Intellectual Property Rights, Cryogen Enhancements or the Licensed Products. Without limiting the generality of the foregoing, CryoCor shall
(i) have the right to receive, from time to time, full and complete information from Cryogen concerning the status of such suit, (ii) have the right, at its sole cost and expense, to be represented therein by separate counsel in advisory or
consultative capacity, and (iii) cooperate fully with Cryogen and provide whatever assistance is reasonably requested by Cryogen in connection with such suit, including the preparation and signing of documents. Cryogen shall have the right to settle
any infringement suit described in either Section 3.2(a)(i) or Section 3.2(a)(ii) hereof in its sole discretion, after reasonable prior consultation with CryoCor and good faith consideration of CryoCor’s requests and proposals.

  
 4. PROSECUTION MAINTENANCE AND ENFORCEMENT WITH RESPECT TO ENHANCEMENTS

  
 4.1 Prosecution of CryoCor Enhancement Patent
Applications. CryoCor agrees to use commercially reasonable efforts to maintain and enforce all issued patents included in the CryoCor Enhancements (each a “Covered Enhancement Issued Patent”) and to use commercially 

 

					
	 	 	5.	 	* Confidential Treatment Requested

 reasonable efforts to prosecute all patent applications included in the CryoCor Enhancements (each a “Covered
Enhancement Patent Application”), all at the sole cost and expense of CryoCor. The drafting, filing, and prosecution of any Covered Enhancement Patent Application shall be CryoCor’s responsibility and shall be carried out by it in its
reasonable discretion, subject to an obligation on the part of CryoCor to keep Cryogen reasonably informed of all material developments with respect to the foregoing activities. Without limiting the generality of the foregoing, CryoCor shall provide
to Cryogen reasonable opportunity to advise CryoCor in the prosecution, filing and maintenance of the Covered Enhancement Issued Patents and the Covered Enhancement Patent Applications and CryoCor shall implement Cryogen’s requests if and to
the extent that such requests are feasible, reasonable and not in conflict with the policies and objectives of CryoCor as determined by CryoCor; provided, however, Cryogen shall be solely responsible for any and all fees, costs and expenses incurred
by CryoCor with respect to the implementation of any such requests by Cryogen. Notwithstanding the foregoing, if CryoCor determines that it no longer desires to prosecute a Covered Enhancement Patent Application or maintain a Covered Enhancement
Issued Patent, it shall, by giving Cryogen corresponding notice in writing, offer to Cryogen the assignment of its right, title and interest in such Covered Enhancement Patent Application or Covered Enhancement Issued Patent, as the case may be. If
Cryogen accepts such offer within sixty (60) days after CryoCor gives such notice, CryoCor shall assign to Cryogen all of CryoCor’s right, title and interest in such Covered Enhancement Patent Application or Covered Enhancement Issued Patent
(subject to an irrevocable, perpetual, royalty-free, exclusive, unrestricted, sublicensable, worldwide license in favor of CryoCor for applications for Licensed Products), at no charge to Cryogen. Following any such assignment, CryoCor may draft,
file, maintain, prosecute and defend such assigned Covered Enhancement Patent Application or Covered Enhancement Issued Patent, as the case may be, in it sole discretion. Pending receipt of a response from Cryogen as to whether Cryogen will accept
such offer or, if later, the expiration of sixty (60) day period, CryoCor shall use reasonable efforts to extend any deadlines or take such action as may be reasonably required to prevent the abandonment of any such Covered Enhancement Patent
Application or forfeiture of any such Covered Enhancement Issued Patent. 
  
 4.2 Infringement of CryoCor Enhancements by Third Parties. 
  
 (a) Cryogen will promptly notify CryoCor in writing of any apparent infringement, misappropriation or other wrongful exploitation of the CryoCor
Enhancements by a third party. 
  
 (i) CryoCor shall have
the initial right, at its sole cost and expense, to determine whether to bring suit to enjoin such infringement, misappropriation or wrongful exploitation and recover damages therefor. CryoCor will bring such action in its name, at its sole cost and
expense, and will take such other action, at its sole cost and expense in connection with the prosecution of such action. Any damages recovered in such action will be payable to CryoCor for its exclusive benefit. 
  
 (ii) If CryoCor does not bring any such action as provided in
Section 4.2(a)(i) above, within [...***...] after written notice of infringement, misappropriation or wrongful exploitation is given by Cryogen, Cryogen may cause CryoCor, at Cryogen’s sole cost and expense to bring suit in
CryoCor’s name or Cryogen’s and CryoCor’s names to enjoin such 
  

					
	 	 	6.	 	* Confidential Treatment Requested

 infringement, misappropriation or wrongful exploitation and recover damages therefor (the “Total Enhancement
Damages”), which shall be for Cryogen’s sole account to the extent the damages are attributable to use and exploitation of the CryoCor Enhancements within the Cryogen Fields (the “Cryogen Enhancement Damages”) and
shall be for the account of CryoCor to the extent the damages are attributable to use and exploitation of the CryoCor Enhancements within the CryoCor Field (the “CryoCor Enhancement Damages”) upon CryoCor’s reimbursement to
Cryogen of CryoCor’s proportionate share of the costs and expenses of such action equal to the CryoCor Enhancement Damages divided by the Total Enhancement Damages. 
  
 (b) In any action brought by CryoCor pursuant to either Section 4.2(a)(i) or Section 4.2(a)(ii) hereof,
CryoCor shall select and control counsel for the prosecution of such suit. CryoCor agrees to keep Cryogen reasonably informed of any and all material developments with respect to any such action or suit, all at the sole cost and expense of Cryogen,
and shall give Cryogen the opportunity to review in advance all major decisions, positions or actions that CryoCor wishes to take in any such action or suit which would impair any interest of Cryogen in the CryoCor Enhancements. Without limiting the
generality of the foregoing, Cryogen shall (i) have the right to receive, from time to time, full and complete information from CryoCor concerning the status of such suit, (ii) have the right, at its sole cost and expense, to be represented therein
by separate counsel in advisory or consultative capacity, and (iii) cooperate fully with CryoCor and provide whatever assistance is reasonably requested by CryoCor in connection with such suit, including the preparation and signing of documents.
CryoCor shall have the right to settle any infringement suit described in either Section 4.2(a)(i) or Section 4.2(a)(ii) hereof in its sole discretion, after reasonable prior consultation with Cryogen and good faith consideration of
Cryogen’s requests and proposals. 
  
 4.3 Prosecution of
Joint Enhancement Patent Applications. Each of Cryogen and CryoCor agrees to use commercially reasonable efforts to jointly maintain and jointly enforce all issued patents included in the Joint Enhancements (each a “Covered Joint
Enhancement Issued Patent”) and to use commercially reasonable efforts to prosecute all patent applications included in the Joint Enhancements (each a “Covered Joint Enhancement Patent Application”), the costs and expenses
of which shall be borne equally by Cryogen and CryoCor. The drafting, filing, and prosecution of any Covered Joint Enhancement Patent Application shall be the shared responsibility of Cryogen and CryoCor and shall be carried out by them in good
faith and with joint cooperation, subject to an obligation on the part of each party to keep the other party reasonably informed of all material developments with respect to the foregoing activities. Without limiting the generality of the foregoing,
each party shall provide the other party with reasonable opportunity to provide advice in the prosecution, filing and maintenance of the Covered Joint Enhancement Issued Patents and the Covered Joint Enhancement Patent Applications and the parties
shall implement one another’s requests if and to the extent that such requests are feasible and reasonable. Notwithstanding the foregoing, if either party (a “Tendering Party”) determines that it no longer desires to jointly
prosecute a Covered Joint Enhancement Patent Application or jointly maintain a Covered Joint Enhancement Issued Patent, it shall, by giving the other party corresponding notice in writing, offer to the other party the assignment of its undivided
right, title and interest in such Covered Joint Enhancement Patent Application or Covered Joint Enhancement Issued Patent, as the case may be. If such other party accepts such offer within [...***...] after its receipt of such notice, such
Tendering Party shall 
  

					
	 	 	7.	 	* Confidential Treatment Requested

 assign to such other party all of the Tendering Party’s undivided right, title and interest in such Covered Joint
Enhancement Patent Application or Covered Joint Enhancement Issued Patent (subject to an irrevocable, perpetual, royalty-free, exclusive, unrestricted, sublicensable, worldwide license in favor of the Tendering Party for either applications for
Licensed Products (if such Tendering Party is CryoCor) or applications for other than Licensed Products (if such Tendering Party is Cryogen), as the case may be), at no charge to such other party. Following any such assignment, such other party may
draft, file, maintain, prosecute and defend, or abandon, such assigned Covered Joint Enhancement Patent Application or Covered Joint Enhancement Issued Patent, as the case may be, in its sole discretion. Pending receipt of a response from such other
party as to whether such other party will accept such offer or, if later, the expiration of [...***...] period, the Tendering Party shall use reasonable efforts to assist such other party in extending any deadlines or taking such action as may
be reasonably required to prevent the abandonment of any such Covered Joint Enhancement Patent Application or forfeiture of any such Covered Joint Enhancement Issued Patent. 
  
 4.4 Infringement of Joint Enhancements by Third Parties. Each party will promptly notify the other party in writing
of any apparent infringement, misappropriation or other wrongful exploitation of a Joint Enhancement by a third party. Cryogen and CryoCor shall jointly determine in good faith whether to bring suit to enjoin such infringement, misappropriation or
wrongful exploitation and recover damages therefor. Cryogen and CryoCor will jointly bring such action in their names, the cost and expense of which shall be borne equally by Cryogen and CryoCor. Any damages recovered in such action will be shared
equally by Cryogen and CryoCor. Cryogen and CryoCor shall jointly select and jointly control counsel for the prosecution of such suit and shall settle any such suits only upon joint agreement. Each party agrees to keep the other party reasonably
informed of any and all material developments with respect to any such action or suit, and each party shall be given the opportunity to review in advance all major decisions, positions or actions that either party wishes to take in any such action
or suit. 
  
 5. REPRESENTATIONS, WARRANTIES AND DISCLAIMERS 
  
 5.1 NO WARRANTY. EXCEPT AS EXPRESSLY PROVIDED BY CRYOGEN IN SECTION 4
OF THE CONTRIBUTION AGREEMENT AND IN THIS SECTION 5, ALL CRYOGEN INTELLECTUAL PROPERTY RIGHTS SHALL BE PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND AND CRYOGEN MAKES NO WARRANTIES WITH RESPECT TO THE CRYOGEN INTELLECTUAL
PROPERTY RIGHTS, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANT ABILITY NONINFRINGEMENT, FITNESS FOR A PARTICULAR PURPOSE OR THE VALIDITY OR ENFORCEABILITY OF ANY PATENTS ISSUED OR APPLIED FOR IN CONNECTION WITH THE CRYOGEN
INTELLECTUAL PROPERTY RIGHTS. 
  
 5.2 Neither party
warrants or represents or shall be deemed to have represented or warranted that the rights granted hereunder will result in commercially acceptable or marketable product lines. 
  

					
	 	 	8.	 	* Confidential Treatment Requested

 5.3 This Agreement does not confer by implication, estoppel, laches or by any other means any
license or any rights other than those expressly granted herein. 
  
 5.4 Without limiting or restricting the covenants and agreements of CryoCor set forth in Section 7.1 hereto, Cryogen represents and warrants that each of the Contributed Clinical Development Products (as such term is defined
in the Contribution Agreement) has been manufactured in accordance with the existing specifications of Cryogen for such Contributed Clinical Development Products. 
  
 5.5 Each patent and patent application owned by Cryogen and used or useful in the CryoCor Field constitutes a part of
the Cryogen Intellectual Property Rights as set forth and described on Exhibit A hereto. The representations and warranties of Cryogen contained in Section 4.5 of the Contribution Agreement are incorporated herein by reference. 
  
 6. CONFIDENTIALITY 
  
 6.1 Any and all files and records pertaining to the Cryogen Intellectual Property Rights previously or hereafter
provided by Cryogen to CryoCor or any of its officers, directors, employees, consultants, stockholders or representative shall be treated as “Confidential Information” of Cryogen by CryoCor. 
  
 6.2 Confidentiality Obligations. 
  
 (a) Any party to this Agreement (the “Disclosing
Party”) may from time to time disclose Confidential Information to the other party to this Agreement (each a “Recipient”). “Confidential Information” is all nonpublic information concerning the unpatented
intellectual property (and any and all rights therein or applications thereof), product specifications, any and all know-how, methods and processes with respect to products and marketing plans and marketing strategies and general market data of the
Disclosing Party which is conveyed to the Recipient orally or in tangible form. Recipient shall keep in confidence and trust and shall not disclose or disseminate, or permit any employee, agent or other person working under Recipient’s
direction to disclose or disseminate, the existence, source, content or substance of any Confidential Information to any other person or entity. Recipient shall use Confidential Information of the Disclosing Party only as necessary for the
performance of this Agreement, the Contribution Agreement of even date herewith between the parties hereto (the “Contribution Agreement”) and the Development Agreement of even date herewith between the parties hereto (together with
the Contribution Agreement, the “Related Agreements”); provided, however, a Recipient may disclose Confidential Information to one or more potential financing sources upon the prior written consent of the Disclosing Party which
consent shall not be unreasonably withheld or delayed. Recipient shall employ at least the same methods and degree of care, but no less than a reasonable degree of care, to prevent disclosure of the Confidential Information as Recipient employs with
respect to its own confidential trade secrets and proprietary information. Recipient’s employees and independent contractors shall be given access to the Confidential Information only on a need-to-know basis, and only if they have executed a
form of nondisclosure agreement with Recipient which imposes a duty to maintain the confidentiality of the Confidential Information that is at least as restrictive as the terms of this Section 6.2. 
  

 9. 

 (b) The commitments in this Section 6.2 shall not impose any obligations on Recipient with
respect to any portion of the received information which: (i) is now generally known by or available to the public or which hereafter, through no act or failure to act on the part of Recipient, becomes generally known or available in the public
domain; (ii) is furnished to Recipient by a third party without restriction on disclosure and without a breach by such third party of any confidentiality undertaking with respect thereto; or (iii) is required to be disclosed by operation of law or
by an instrumentality of the government, including but not limited to any court, tribunal or administrative agency; provided that, in the case of any disclosure required by court order, the Recipient shall give the Disclosing Party as much advance
notice as is reasonably practicable under the circumstances so as to permit the Disclosing Party to seek a protective order. 
  
 (c) The terms of Section 6.2 of the Contribution Agreement shall control in the event of a conflict between this Section 6.2 and the
confidentiality and non-disclosure agreements contained in the Related Agreements (or any of them). 
  
 (d) The obligations of the parties hereto under this Section 6.2 shall survive indefinitely. 
  
 7. PRODUCT LIABILITY AND INDEMNIFICATION 
  
 7.1 Product Defects. With respect to Licensed Products conceived,
developed, manufactured or sold after the Effective Date, CryoCor will have full responsibility for determining that the designs of the Licensed Products and components made by or for CryoCor are manufactured in accordance with customary commercial
standards. 
  
 7.2 Indemnity. 
  
 (a) CryoCor hereby agrees to indemnify and hold harmless Cryogen and
its Affiliates and their respective officers, directors, employees, consultants and shareholders from and against any and all claims, demands, and actions, and any liabilities, damages, or expenses resulting therefrom, including court costs and
reasonable attorneys’ fees and expenses (collectively “Damages”), resulting from the conception, development, manufacture, sale, offer to sell, distribution, importation or use of the Cryogen Intellectual Property Rights, the
Cryogen Enhancements or the Joint Enhancements by CryoCor or its Affiliates, including, without limitation, any Damages based upon or relating to Licensed Products or any other products or services provided or offered by CryoCor. CryoCor’s
obligations under this Section 7.2(a) shall survive the termination of this Agreement for any reason. Cryogen agrees to give CryoCor prompt notice of any such claim, demand, or action and to cooperate in the defense and settlement of said
claim, demand, or action as reasonably requested by CryoCor, provided, that CryoCor shall reimburse Cryogen for all reasonable expenses incurred as a result of such cooperation. 
  
 (b) Cryogen hereby agrees to indemnify and hold harmless CryoCor and its Affiliates and their respective officers,
directors, employees, consultants and shareholders from and against any and all Damages, resulting from the conception, development, manufacture, sale, offer to sell, distribution, importation or use of the CryoCor Enhancements or the Joint

  

 10. 

 Enhancements by Cryogen or its Affiliates, including, without limitation, any Damages based upon or relating to products
or services provided or offered by Cryogen. Cryogen’s obligations under this Section 7.2(b) shall survive the termination of this Agreement for any reason. CryoCor agrees to give Cryogen prompt notice of any such claim, demand, or action
and to cooperate in the defense and settlement of said claim, demand, or action as reasonably requested by Cryogen, provided, that Cryogen shall reimburse CryoCor for all reasonable expenses incurred as a result of such cooperation. 
  
 7.3 Insurance. 
  
 (a) CryoCor shall maintain at all times during the period that any
Licensed Products are being distributed or sold by CryoCor hereunder, and thereafter for the time any such Licensed Products remain in clinical use, comprehensive general liability insurance, with endorsements for contractual liability and product
liability with coverage limits of not less than [...***...]. Cryogen shall, under such insurance, be named as an additional insured with a cross-liability endorsement. The minimum level of insurance set forth herein shall not be construed to
create a limit on CryoCor’s liability with respect to its indemnification obligations hereunder. Prior to the commencement of clinical use (including commencement of human clinical trials) of Licensed Products, and on each subsequent
anniversary of the Effective Date, CryoCor shall furnish to Cryogen a certificate of insurance evidencing such coverage as of the date of commencement of such clinical use (and each anniversary thereof) and upon request by Cryogen at any time
hereafter. Each such certificate of insurance shall include a provision whereby sixty (60) days written notice must be received by Cryogen prior to coverage modification or cancellation by either CryoCor or the insurer. 
  
 (b) Cryogen shall maintain at all times during the period that any
products utilizing any of the CryoCor Enhancements or the Joint Enhancements are being distributed or sold by Cryogen hereunder, and thereafter for the time any such products remain in clinical use, comprehensive general liability insurance, with
endorsements for contractual liability and product liability with coverage limits of not less than [...***...]. CryoCor shall, under such insurance, be named as an additional insured with a cross-liability endorsement. The minimum level of
insurance set forth herein shall not be construed to create a limit on Cryogen’s liability with respect to its indemnification obligations hereunder. Prior to the commencement of clinical use (including commencement of human clinical trials) of
products utilizing CryoCor Enhancements, Cryogen shall furnish to CryoCor a certificate of insurance evidencing such coverage as of the date of commencement of such clinical use (and each anniversary thereof) and upon request by CryoCor at any time
hereafter. Each such certificate of insurance shall include a provision whereby sixty (60) days written notice must be received by CryoCor prior to coverage modification or cancellation by either Cryogen or the insurer. 
  
 8. GENERAL PROVISIONS 
  
 8.1 Governing Law; Consent to Jurisdiction. This Agreement shall be governed by and construed in accordance with the
laws of the State of California without regard to conflicts of law principles. Any action or proceeding, however characterized, relating to or arising out of this Agreement, or in connection with the subject matter hereof shall be maintained in the
state or federal courts located in San Diego County, California, and the parties hereto, each for itself, 
  

					
	 	 	11.	 	* Confidential Treatment Requested

 its successors and permitted assigns, hereby irrevocably submits to the jurisdiction of the courts of the State of
California and the Courts of the United States of America sitting in the San Diego County, California for the purposes of any such action or proceeding and irrevocably agrees to be bound by any judgment rendered thereby in connection with this
Agreement. 
  
 8.2 Assignment. Neither this Agreement nor
the licenses granted hereunder may be assigned by either party without the prior written consent of the other party, except that upon a merger, or acquisition of all or substantially all of the capital stock or assets of a party, such consent shall
not be required. 
  
 8.3 Enhancements. 
  
 (a) The parties hereto acknowledge that CryoCor intends to commit
such resources and personnel as CryoCor shall deem appropriate to design and make such modifications, improvements and enhancements to the Cryogen Intellectual Property Rights and/or Licensed Products as shall be necessary in order to meet
CryoCor’s customers’ requirements. Beginning on the date hereof and continuing until [...***...], CryoCor covenants and agrees to promptly (i) notify Cryogen of each such modification, improvement or enhancement and (ii) prepare and
provide to Cryogen a Written Idea Memorandum with respect to each such modification, improvement or enhancement, in each case, upon the discovery or development of any such modification, improvement or enhancement. With respect to any such
modification, improvement or enhancement that is a CryoCor Enhancement (as defined in Section 1.3 hereof) or a Joint Enhancement (as defined in Section 1.13 hereof), CryoCor does further covenant and agree to provide to Cryogen access
to all drawings, specifications, technology and know-how related to such CryoCor Enhancement or Joint Enhancement, so as to enable Cryogen to fully use and exploit such CryoCor Enhancement and Joint Enhancement pursuant to Sections 2.2 and
2.3 hereof. CryoCor shall own all CryoCor Enhancements and shall have full rights as the owner thereof to fully use and exploit the CryoCor Enhancements in whatever manner it shall deem appropriate, subject to Cryogen’s rights, as
granted pursuant to Sections 2.2 and 2.3 hereof, to fully use and exploit the CryoCor Enhancements in whatever manner it shall deem appropriate within the Cryogen Fields. 
  
 (b) The parties hereto acknowledge that Cryogen may commit such resources and personnel as Cryogen shall deem
appropriate to design and make such modifications, improvements and enhancements to the Cryogen Intellectual Property Rights as may be necessary in order to meet Cryogen’s or its customers’ requirements. Beginning on the date hereof and
continuing until [...***...], Cryogen covenants and agrees to promptly (i) notify CryoCor of each such modification, improvement or enhancement and (ii) prepare and provide to CryoCor a Written Idea Memorandum with respect to each such
modification, improvement or enhancement, in each case, upon the discovery or development of any such modification, improvement or enhancement. With respect to any such modification, improvement or enhancement that is a Cryogen Enhancement (as
defined in Section 1.5 hereof), or a Joint Enhancement (as defined in Section 1.13 hereof), Cryogen does further covenant and agree to provide to CryoCor access to all drawings, specifications, technology and know-how related to such
Cryogen Enhancements or Joint Enhancements, so as to enable CryoCor to fully use and exploit such CryoCor Enhancements or Joint Enhancements pursuant to Section 2.1 hereof. Cryogen shall own all Cryogen Enhancements and shall have full rights
as the owner thereof to 
  

					
	 	 	12.	 	* Confidential Treatment Requested

 fully use and exploit the Cryogen Enhancements in whatever manner it shall deem appropriate, subject to CryoCor’s
rights, as granted pursuant to Section 2.1 hereof, to fully use and exploit the Cryogen Enhancements in whatever manner it shall deem appropriate within the CryoCor Field. 
  
 (c) Cryogen and CryoCor shall jointly own all Joint Enhancements and shall have equal undivided rights as the joint
owners thereof to fully use and exploit the Joint Enhancements in whatever manner they shall deem appropriate, subject to CryoCor’s rights, as granted pursuant to Section 2.1 hereof, to fully use and exploit the Cryogen Joint Enhancement
Interest in whatever manner it shall deem appropriate within the CryoCor Field, and subject to Cryogen’s rights, as granted pursuant to Sections 2.2 and 2.3 hereof, to fully use and exploit the CryoCor Joint Enhancement Interest
in whatever manner it shall deem appropriate within the Cryogen Fields. 
  
 8.4 No Waiver. Failure by either party to enforce any provision of this Agreement will not be deemed a waiver of future enforcement of that or any other provision. 
  
 8.5 Independent Contractors. The relationship of Cryogen and CryoCor established by this Agreement is that of
independent contractors, and nothing contained in this Agreement shall be construed (i) to give either party the power to direct or control the day-to-day activities of the other or (ii) to constitute the parties as partners, joint venturers,
co-owners or otherwise as participants in a joint or common undertaking. 
  
 8.6 Section Headings. The section headings contained herein are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
  
 8.7 Interpretation. The parties agree that this Agreement shall be
fairly interpreted in accordance with its terms without any strict construction in favor of or against either party and that ambiguities shall not be interpreted against the drafting party. 
  
 8.8 Severability. If for any reason a court of competent jurisdiction
finds any provision of this Agreement, or portion thereof, to be unenforceable, that provision of the Agreement will be enforced to the maximum extent permissible so as to effect the intent of the parties, and the remainder of this Agreement will
continue in full force and effect. 
  
 8.9 Attorneys’
Fees. The prevailing party in any action to enforce the Agreement shall be entitled to recover costs and expenses including, without limitation, reasonable attorneys’ fees. 
  
 8.10 Injunctive Relief. The parties agree that a material default of the provisions of this Agreement by a party
hereto could cause irreparable injury to the other party for which monetary damages would not be an adequate remedy and such other party shall be entitled to seek equitable relief, including injunctive relief and specific performance, in addition to
any remedies it may have hereunder or at law. 
  
 8.11
Notices. Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Agreement shall be in writing and shall be conclusively deemed to have been duly given: (a) when hand delivered to
the other party; (b) when received when sent by facsimile at the address set forth below; (c) three (3) business 
  

 13. 

 days after deposit in the U.S. mail with first class or certified mail receipt requested postage prepaid and addressed to
the other party as set forth below; or (d) the next business day after deposit with a national overnight delivery service, postage prepaid, addressed to the parties as set forth below with next-business-day delivery guaranteed, provided that the
sending party receives a confirmation of delivery from the delivery service provider. 
  

			
	 To CryoCor:

		
	 	  	 c/o MPM Asset Management LLC
 601 Gateway Blvd., Suite
300
 South San Francisco, CA 94080
 Facsimile: (650)
829-5828
 Attention: Gregory M. Ayers, M.D., Ph.D.

	
	 With copies to:

		
	 	  	 Gray Cary Ware & Freidenrich LLP
 4365 Executive
Drive, Suite 1600
 San Diego, California 92121
 Facsimile: (858)
677-1477
 Attention: Paul E. Kreutz, Esq.

	
	 To Cryogen:

	 	  	 Cryogen, Inc.
 11065 Sorrento Valley Court

San Diego, California 92121
 Facsimile: (858) 450-3187
 Attention: President

	
	 With copies to:

		
	 	  	 Brobeck, Phleger & Harrison LLP
 12390 El Camino
Real
 San Diego, California 92130
 Facsimile: (858)
720-2555
 Attention: Michael S. Kagnoff, Esq.

  
 Each person making a
communication hereunder by facsimile shall promptly confirm by telephone to the person to whom such communication was addressed each communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the
validity of any such communication. A party may change or supplement the addresses given above, or designate additional addresses, for purposes of this Section 8.11 by giving the other party written notice of the new address in the manner set
forth above. 
  

 14. 

 8.12 Patent Marking. 
  
 (a) CryoCor shall mark all Licensed Products made, used, sold, offered for sale, or imported under the terms of this
Agreement, and for their containers and packaging, in accordance with the applicable patent marking laws and regulations of the jurisdiction in which such Licensed Products are made, sold, offered for sale or imported. 
  
 (b) Cryogen shall mark all products utilizing any of the CryoCor
Enhancements made, used, sold, offered for sale, or imported under the terms of this Agreement, and or their containers and packaging, in accordance with the applicable patent marking laws and regulations of the jurisdiction in which such products
are made, sold, offered for sale or imported. 
  
 8.13 Entire
Agreement. This Agreement, including any Exhibits attached hereto, which are hereby incorporated by reference, constitutes the entire understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements or
representations, oral or written, regarding such subject matter. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of both parties. 
  
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by
their duly authorized representatives: 
  

									
	CRYOGEN INC.	 	 	 	CRYOCOR, INC.
					
	By:	 	 /s/    DAVID R. MURRAY

	 	 	 	By:	 	 /s/    GREGORY M. AYERS

					
	Name:	 	 David R. Murray

	 	 	 	Name:	 	 Gregory M. Ayers

					
	Title:	 	 President & CEO

	 	 	 	Title:	 	 President & CEO

  
  

 15. 

 EXHIBIT A 
  

CRYOGEN INTELLECTUAL PROPERTY RIGHTS 
  

									
	 TITLE

	 	 DOCKET
 NUMBER

	 	 PUB./
 PATENT #

	 	 TYPE

	 	 FILING/
 ISSUE DATE

	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 	 	 	 	 	 	 	 	 

	*	Indicates patents or patent applications that are jointly owned by Cryogen and NIST. The rights granted to CryoCor under Section 2.1 of this Agreement are exclusive rights under
Cryogen’s ownership interest in the indicated patents and patent applications. NIST has exclusively licensed its rights to the indicated patents and patent applications to Cryogen under the terms of the NIST License Agreement. Pursuant to
Section 2.5 of this Agreement, upon CryoCor’s request, Cryogen has agreed to exclusively sublicense its rights under the NIST License Agreement to CryoCor subject to receipt of necessary approvals from NIST of such sublicense.

 [...***...] 
  

					
	 	 	1.	 	* Confidential Treatment RequestedResearch and Development Agreement

 EXHIBIT 10.16 
  
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested 
 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 230.406 
  
 RESEARCH AND DEVELOPMENT AGREEMENT 
  
 This Research and Development Agreement (the “Agreement”) is made and entered into as of August 31, 2000 (the “Effective Date”), by and between Cryogen, Inc., a California corporation
(“Cryogen”), and CryoCor, Inc., a Delaware corporation (“CryoCor”). 
  
 RECITALS 
  
 WHEREAS,
Cryogen and CryoCor are parties to the Contribution Agreement and the License Agreement. 
  
 WHEREAS Cryogen has granted to CryoCor, and CryoCor has acquired from Cryogen a license to Cryogen Intellectual Property Rights for the purpose of allowing CryoCor to develop Technology and to develop and
commercialize Licensed Products based on such Technology solely for use in the CryoCor Field. 
  
 WHEREAS, Cryogen has experience in the development of such products and has the facilities, equipment, employees and other resources to accomplish development activities, on behalf of CryoCor, with respect to the
Technology and the Licensed Products. 
  
 WHEREAS, CryoCor may
desire to engage Cryogen to perform such services, from time to time on an as needed basis, in connection with the development activities, and Cryogen is willing to provide such services. 
  
 NOW, THEREFORE, in consideration of the mutual covenants set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, and in order to induce Cryogen to enter into the Agreements, Cryogen and CryoCor hereby agree as follows: 
  
 1. Definitions. 
  
 1.1 Definitions. All capitalized terms used herein and not otherwise defined shall have the respective meanings, to the extent such
terms are used herein, set forth in Schedule 1 attached hereto, which is incorporated by this reference as though fully set forth herein. 
  
 1.2 Singular and Plural. Singular and plural forms, as the case may be, of terms defined herein shall have correlative meanings.

  
 2. Development Services. 
  
 2.1 Development. Beginning on the Effective Date and
ending upon the termination of this Agreement (or a portion hereof), as provided herein below, Cryogen shall, at the sole cost and expense of CryoCor, provide the support and services set forth and described on Schedule 3 hereto on an as
needed and billed for as used basis; provided, that Cryogen will have no obligation to provide support and services in excess of the maximum commitments set forth on Schedule 3. Notwithstanding the last clause of the immediately preceding
sentence, Cryogen 

  

 1 

 
will reasonably attempt to supply additional support and services as may be requested by CryoCor so long as any such requests do not conflict with or
interfere with the conduct of Cryogen’s business. In the event that CryoCor utilizes any of the individual support or services set forth and described on Schedule 3 hereto at less than the minimum rate described for any such support or
service (e.g., the support of a particular employee or of a particular service) during any period of two (2) consecutive months, Cryogen will provide a written notice of such failure to CryoCor (a “Utilization Failure Notice”). After
CryoCor’s receipt of a Utilization Failure Notice, Cryogen shall have the right and option to cease provision of the services of the particular employee or other service item which is the subject of such Utilization Failure Notice unless
CryoCor notifies Cryogen in writing of its agreement to pay Cryogen an amount equal to the minimum amount that Cryogen would otherwise be entitled to receive from CryoCor for providing such support or service notwithstanding CryoCor’s failure
to utilize such support or service at the minimum rate described on Schedule 3. Unless otherwise extended by written agreement of Cryogen and CryoCor, this Agreement shall automatically terminate in full on the first anniversary of the
Effective Date; provided, however, the obligation of Cryogen to provide the tasks and services set forth on Schedule 3 hereto shall automatically terminate upon the expiration of the periods for the performance of such tasks and services as
described on Schedule 3 hereto or any written amendment thereto. 
  
 2.1.1 Conduct of Development. All activities performed under this Agreement will be conducted under the direction of CryoCor’s management. While specific Cryogen employees may from time to time be involved
in providing the support and services contemplated by this Agreement and, in connection therewith, may from time to time, have certain leadership responsibilities, CryoCor hereby expressly assumes all responsibility for all aspects of the
development contemplated by this Agreement, including, without limitation, direction and timing of such development. Without limiting the generality of the foregoing, CryoCor will be solely responsible for determining the suitability and timing of
the use of Licensed Products or other products of CryoCor on human patients. 
  
 2.1.2 Sale of Licensed Products. Licensed Products that are Manufactured pursuant to the terms of this Agreement by Cryogen or within facilities owned and operated by Cryogen will not be marketed and sold
commercially but will be used to conduct the clinical testing required to obtain regulatory approval to market such Licensed Products. 
  
 2.2 Disclaimer of Warranties. Cryogen cannot and does not guarantee that the development of the Technology or the Licensed Products
will be successful in whole or in part, that any Licensed Products will be developed or that any developed Licensed Products will be successful in the marketplace. The failure of Cryogen to further develop successfully the Technology or to discover,
develop or commercialize any Licensed Product will not in and of itself constitute a breach by Cryogen of any representation, warranty, covenant or other obligation under the Agreements. 
  
 2.3 Rights to Property. Any and all Cryogen Enhancements (as such term is defined in the License
Agreement) shall be the sole and exclusive property of Cryogen, subject to CryoCor’s rights as granted pursuant to Section 2.1 of the License Agreement, and any and all CryoCor Enhancements (as such term is defined in the License Agreement)
shall be the sole and exclusive property of CryoCor, subject to Cryogen’s rights as granted pursuant to Sections 2.2 

  

 2 

 
and 2.3 of the License Agreement. Cryogen and CryoCor shall jointly own all Joint Enhancements (as such term is defined in the License Agreement) and shall
have equal undivided rights as the joint owners thereof to fully use and exploit the Joint Enhancements in whatever manner they shall deem appropriate, subject to CryoCor’s rights, as granted pursuant to Section 2.1 of the License
Agreement, to fully use and exploit the Cryogen Joint Enhancement Interest (as such term is defined in the License Agreement) in whatever manner it shall deem appropriate within the CryoCor Field, and subject to Cryogen’s rights, as granted
pursuant to Sections 2.2 and 2.3 of the License Agreement, to fully use and exploit the CryoCor Joint Enhancement Interest (as such term is defined in the License Agreement) in whatever manner it shall deem appropriate within the
Cryogen Fields. Any and all Other Enhancements (as such term is defined in the License Agreement) shall be the sole and exclusive property of the party that makes or discovers any such Other Enhancement and any such Other Enhancement shall not be
subject to the licenses granted under the License Agreement to Cryogen (pursuant to Sections 2.2 and 2.3 of the License Agreement) and to CryoCor (pursuant to Section 2.1 of the License Agreement), respectively. Notwithstanding the foregoing, any
submissions or applications to any regulatory authority made by Cryogen in its name on behalf of CryoCor for intellectual property rights not developed by Cryogen pursuant to this Agreement or Licensed Products that are manufactured by Cryogen on
behalf of CryoCor pursuant to this Agreement, shall be the exclusive property of CryoCor. 
  
 2.4 License. The parties hereto shall grant certain licenses to each other upon the terms and as set forth in Section 2 of the
License Agreement. 
  
 3. Payment for Services; Timing of
Payments; Records. 
  
 3.1 Payments for
Services. In consideration of the services to be provided by Cryogen during the term of this Agreement, CryoCor shall reimburse Cryogen for all Costs associated with such services. 
  
 3.2 Timing of Payments. CryoCor shall pay to Cryogen monthly the Costs incurred in the prior month as
shown on a statement delivered by Cryogen to CryoCor. CryoCor shall make such payment within thirty (30) days after the delivery of such statement from Cryogen. 
  
 3.3 Calculation of Costs. Costs shall be determined in accordance with Schedule 2 hereto.

  
 3.4 Records. Cryogen shall keep and
maintain proper and complete records and books of account documenting all of its expenses related to the services provided hereunder, including those allocated to and reimbursed by CryoCor hereunder. At CryoCor’s request and expense, Cryogen
shall permit a certified independent public accountant selected by CryoCor to have access, no more than once in each calendar year during the term of this Agreement and each year for three (3) calendar years following the termination hereof, during
regular business hours and upon reasonable notice to Cryogen, to such records and books for the sole purpose of determining the appropriateness of Costs invoiced hereunder; provided, however, that if such certified independent public accountant
reasonably determines that such Costs have been, for any calendar year, after adjustments herein provided for, overstated by Cryogen, Cryogen shall (1) 

  

 3 

 
promptly refund any such overpayment to CryoCor, and (2) if such Costs were overstated by Cryogen by an amount equal to or greater than five percent (5%),
Cryogen shall also pay all reasonable fees and disbursements of such certified independent public accountant incurred in the course of making such determination. 
  
 4. Representations, Warranties and Covenants. The provisions of Sections 3, 4 and 9.1 of the Contribution Agreement
with respect to Cryogen and CryoCor shall apply with equal force and effect to this Agreement and are incorporated hereunder. 
  
 5. Mutual Confidentiality. 
  
 5.1 Confidentiality Obligations Any party to this Agreement (the “Disclosing Party”) may from time to time disclose
Confidential Information to the other party to this agreement (each a “Recipient”). “Confidential Information” is all nonpublic information concerning the unpatented intellectual property (and any and all rights therein or
applications thereof), product specifications, any and all know-how, methods and processes with respect to products and marketing plans and marketing strategies and general market data of the Disclosing Party which is conveyed to the Recipient
orally or in tangible form. Recipient shall keep in confidence and trust and shall not disclose or disseminate, or permit any employee, agent or other person working under Recipient’s direction to disclose or disseminate, the existence, source,
content or substance of any Confidential Information to any other person or entity. Recipient shall use Confidential Information of the Disclosing Party only as necessary for the performance of the Agreements; provided, however, a Recipient may
disclose Confidential Information to one or more potential financing sources upon the prior written consent of the Disclosing Party which consent shall not be unreasonably withheld or delayed. Recipient shall employ at least the same methods and
degree of care, but no less than a reasonable degree of care, to prevent disclosure of the Confidential Information as Recipient employs with respect to its own confidential trade secrets and proprietary information. Recipient’s employees and
independent contractors shall be given access to the Confidential Information only on a need-to-know basis, and only if they have executed a form of non-disclosure agreement with Recipient which imposes a duty to maintain the confidentiality of the
Confidential Information that is at least as restrictive as the terms of this Section 5. 
  
 The commitments in this Section 5 shall not impose any obligations on Recipient with respect to any portion of the received information which: (i) is now generally known by or available to the public or which
hereafter, through no act or failure to act on the part of Recipient, becomes generally known or available in the public domain; (ii) is furnished to Recipient by a third party without restriction on disclosure and without a breach by such third
party of any confidentiality undertaking with respect thereto; or (iii) is required to be disclosed by operation of law or by an instrumentality of the government, including but not limited to any court, tribunal or administrative agency; provided
that, in the case of any disclosure required by court order, the Recipient shall give the Disclosing Party as much advance notice as is reasonably practicable under the circumstances so as to permit the Disclosing Party to seek a protective order.

  

 4 

 5.2 Conflicting Provisions The terms of Section 6.2 of the Contribution Agreement
shall control in the event of a conflict between this Section 5 and the confidentiality and non-disclosure agreements contained in the Agreements (or any of them). 
  
 6. Disclaimer of Warranty. Neither party warrants or represents or shall be deemed to have represented or warranted
that the rights granted hereunder will result in commercially acceptable or marketable product lines. This Agreement does not confer by implication, estoppel, laches or by any other means any license or any rights other than those expressly granted
herein. 
  
 7. Product Liability and Indemnification;
Insurance. 
  
 7.1 Product Defects.
With respect to Licensed Products conceived, developed, manufactured or sold, whether before or after the Effective Date, CryoCor will have full responsibility for determining that the designs of the Licensed Products and components made by or for
CryoCor are manufactured in accordance with customary commercial standards. 
  
 7.2 Indemnity. The parties hereto shall indemnify each other upon the terms and as set forth in Section 7.2 of the License Agreement. 
  
 7.3 Insurance by CryoCor. CryoCor shall maintain at all times during the period that any Licensed
Products are being distributed or sold by CryoCor, and thereafter for the time any such Licensed Products remain in clinical use, comprehensive general liability insurance, with endorsements for contractual liability and product liability with
coverage limits of not less than Five Million Dollars ($5,000,000). Cryogen shall, under such insurance, be named as an additional insured with a cross-liability endorsement. The minimum level of insurance set forth herein shall not be construed to
create a limit on CryoCor’s liability with respect to its indemnification obligations hereunder. Prior to the commencement of clinical use (including the commencement of human clinical trials) of Licensed Products, and on each subsequent
anniversary of the Effective Date, CryoCor shall furnish to Cryogen a certificate of insurance evidencing such coverage as of the date of commencement of such clinical use (and each anniversary thereof) and upon request by Cryogen at any time
hereafter. Each such certificate of insurance shall include a provision whereby sixty (60) days’ written notice must be received by Cryogen prior to coverage modification or cancellation by either CryoCor or the insurer. 
  
 7.4 Insurance by Cryogen. Cryogen shall, to the
extent available at commercially reasonable rates, maintain, with insurers or underwriters of good repute general liability insurance for the facilities owned or operated by Cryogen in which the Manufacture or development of Licensed Products will
be performed pursuant to this Agreement. 
  
 8. Term and
Termination. 
  
 8.1 Term. This
Agreement shall terminate as provided in Section 2.1 hereof, unless terminated earlier as provided in Sections 8.2 and 8.3 hereof. 
  

 5 

 8.2 Termination By Mutual Agreement. By mutual agreement, the parties hereto may
at any time terminate this Agreement and the developmental or other services provided hereunder on mutually acceptable terms. 
  
 8.3 Termination For Event of Default. Either Cryogen or CryoCor shall have the right to terminate this Agreement, effective as set
forth in a written notice to the other party of the occurrence of an Event of Default with respect to such other party. 
  
 8.4 Effect of Termination. 
  
 8.4.1 Return of Licensed Products. In the event of the termination of this Agreement, Cryogen shall within thirty (30) days of the
effective date of such termination, transfer to CryoCor all Technology and all other data, records and materials in Cryogen’s possession or control which relate to the Licensed Products. Cryogen shall also cooperate in the transfer of
regulatory filings related to such Licensed Products, and take such other actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of such rights to CryoCor. 
  
 8.4.2 Continuing Obligation to Make Payments.
Termination of this Agreement shall not relieve the parties hereto of any liability, including any obligation to pay any amounts payable by any party to another party which accrued prior to such termination, nor preclude any party from pursuing all
rights and remedies it may have hereunder or at law or equity with respect to any breach of this Agreement nor prejudice any party’s right to obtain performance of any obligation. 
  
 9. Miscellaneous. 
  
 9.1 Successors and Assigns. Except as otherwise expressly provided in this Agreement, the provisions of this Agreement shall inure
to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties to this Agreement whose rights or obligations hereunder are affected by such amendments. This Agreement and the rights and
obligations in it may not be assigned by any party hereto without the written consent of the other parties hereto. 
  
 9.2 Entire Agreement. This Agreement and the schedules and exhibits to this Agreement which are hereby expressly incorporated in
this Agreement constitute the entire understanding and agreement between the parties with regard to the subjects hereof and thereof. 
  
 9.3 Notices. Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to
this Agreement shall be in writing and shall be conclusively deemed to have been duly given: (a) when hand delivered to the other party; (b) when received when sent by facsimile at the address set forth below; (c) three (3) business days after
deposit in the U.S. mail with first class or certified mail receipt requested postage prepaid and addressed to the other party as set forth below; or (d) the next business day after deposit with a national overnight delivery service, postage
prepaid, addressed to the parties as set forth below with next-business-day delivery guaranteed, provided that the sending party receives a confirmation of delivery from the delivery service provider. 
  

 6 

 To CryoCor: 
  
 c/o MPM Asset Management LLC 
 601 Gateway
Blvd., Suite 300 
 South San Francisco, CA 94080 
  
 Facsimile: (650) 829-5828 
  
 Attention: Gregory M. Ayers, M.D., Ph.D. 
  
 With copies to: 
  
 Gray Cary Ware & Freidenrich LLP 
 4365
Executive Drive, Suite 1600 
 San Diego, California 92121 
  
 Facsimile: (858) 677-1477 
  
 Attention: Paul E. Kreutz, Esq. 
  
 If to Cryogen: 
  
 Cryogen, Inc. 
 11065 Sorrento Valley Court

 San Diego, California 92121 
  
 Facsimile: (858) 450-3187 
  
 Attention: President 
  
 With copies to: 
  
 Brobeck, Phleger & Harrison LLP 
 12390 El
Camino Real 
 San Diego, California 92130 
  
 Facsimile: (858) 720-2555 
  
 Attention: Michael S. Kagnoff, Esq. 
  
 Each person making a communication hereunder by facsimile shall promptly confirm by telephone to the person to whom such communication was addressed each
communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the validity of any such communication. A party may change or supplement the addresses given above, or designate additional addresses, for
purposes of this Section 9.3 by giving the other party written notice of the new address in the manner set forth above. 
  

 7 

 9.4 Amendments and Waivers. Any term of this Agreement may be amended only with
the written consent of Cryogen and CryoCor. 
  
 9.5 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to CryoCor or to Cryogen, upon any breach or default of any party hereto under this Agreement, shall impair any such right, power or remedy
of CryoCor, or Cryogen nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of any similar breach of default thereafter occurring; nor shall any waiver of any other breach or default theretofore or
thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of CryoCor or Cryogen of any breach of default under this Agreement or any waiver on the part of CryoCor or Cryogen of any provisions or conditions of
this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, or by law or otherwise afforded to CryoCor or Cryogen shall be cumulative and not
alternative. 
  
 9.6 Legal Fees. In the
event of any action at law, suit in equity or arbitration proceeding in relation to this Agreement, the prevailing party, shall be paid by the non-prevailing party a reasonable sum for attorneys’ fees and expenses for such prevailing party.

  
 9.7 Titles and Subtitles. The titles
of the sections, paragraphs and subparagraphs of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 
  
 9.8 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall
be an original, but all of which together shall constitute one instrument. 
  
 9.9 Severability. Should any provision of this Agreement be determined to be illegal or unenforceable, such determination shall not affect the remaining provisions of this Agreement. 
  
 9.10 Governing Law; Consent to Jurisdiction. This
Agreement shall be governed by and construed in accordance with the laws of the State of California without regard to conflicts of law principles. Any action or proceeding, however characterized, relating to or arising out of this Agreement, or in
connection with the subject matter hereof shall be maintained in the state or federal courts located in San Diego County, California, and the parties hereto, each for itself, its successors and permitted assigns, hereby irrevocably submits to the
jurisdiction of the courts of the State of California and the Courts of the United States of America sitting in the San Diego County, California for the purposes of any such action or proceeding and irrevocably agrees to be bound by any judgement
rendered thereby in connection with this Agreement. 
  
 9.11 Survival. Sections 2.3, 2.4, 3, 5, 7, 8 and 9 of this Agreement, and all obligations to pay any amounts due hereunder, shall survive, and shall not be affected by, any termination of this Agreement pursuant to Section 8.

  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 

 8 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

					
	 CRYOGEN, INC.

		
	By:	 	/s/ David R. Murray
	 	 	 Name:
	 	 David R. Murray

	 	 	 Title:
	 	 

  

					
	 CRYOCOR, INC.

		
	By:	 	/s/ Gregory M. Ayers
	 	 	 Name:
	 	 Gregory M. Ayers

	 	 	 Title:
	 	 Pres/CEO

  
 [SIGNATURE
PAGE TO RESEARCH AND DEVELOPMENT AGREEMENT] 
  

 9 

 EXHIBIT A 
  

CRYOGEN INTELLECTUAL PROPERTY RIGHTS 
  

									
	 TITLE

	 	 DOCKET
 NUMBER

	 	 PUB./
 PATENT #

	 	 TYPE

	 	 FILING/
 ISSUE DATE

	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 	 	 	 	 	 	 	 	 

	*	Indicates patents or patent applications that are jointly owned by Cryogen and NIST. The rights granted to CryoCor under Section 2.1 of this Agreement are exclusive rights under
Cryogen’s ownership interest in the indicated patents and patent applications. NIST has exclusively licensed its rights to the indicated patents and patent applications to Cryogen under the terms of the NIST License Agreement. Pursuant to
Section 2.5 of this Agreement, upon CryoCor’s request, Cryogen has agreed to exclusively sublicense its rights under the NIST License Agreement to CryoCor subject to receipt of necessary approvals from NIST of such sublicense.

 [...***...] 
  

					
	 	 	1.	 	* Confidential Treatment Requested

  
 SCHEDULE 1 

 
 GLOSSARY 
  
 “Affiliate” shall mean a corporation, company, or other
legal entity now or hereinafter controlling, controlled by or under common control with a party hereto, for so long as such ownership or control exists. For the purposes of this definition, control shall refer to a greater than 50% interest in the
right to make decisions for such entity (e.g., greater than 50% ownership of the voting shares or other voting securities of such entity). Notwithstanding anything to the contrary contained herein, “Affiliate” shall not include (i) in the
case of Cryogen, CryoCor and (ii) in the case of CryoCor, Cryogen. 
  
 “Agreements” shall mean the Contribution Agreement, the License Agreement and this Research and Development Agreement. 
  
 “Bankruptcy Code” shall mean the United States Bankruptcy Code, as amended from time to time. 
  
 “CryoCor Field” shall mean cardiac or vascular ablation to
treat cardiac arrhythmia. 
  
 “Confidential
Information” shall have the meaning assigned to it in Section 5 of this Agreement. 
  
 “Contribution Agreement” shall mean the Contribution Agreement dated of even date herewith between Cryogen and CryoCor. 
  
 “Costs” shall mean all costs, fees and out-of-pocket or other expenses, including the costs and expenses
for providing the support and services contemplated by Schedule 3 hereto and the purchase of any capital equipment related to the activities and services of Cryogen hereunder, fully-burdened payroll costs (burdened to include benefits,
payroll taxes and an allocation of facilities and overhead costs) and any other such costs generated internally by Cryogen in respect of the activities and services of Cryogen hereunder, including, without limitation, all other costs incurred by
Cryogen or its Affiliates in respect of the activities and services of Cryogen hereunder determined in accordance with the methodology set forth on Schedule 2 attached hereto, and allocated on a reasonable and consistent basis. 
  
 “Cryogen Intellectual Property Rights” shall mean the
intellectual property rights owned by Cryogen used or useful in the CryoCor Field, as particularly set forth and described in Exhibit A hereto. 
  
 “Event of Default” shall mean any of the following events: (a) at any time, if Cryogen or CryoCor fails to perform or observe or
otherwise breaches any of its Material Obligations, and such failure or breach continues unremedied for a period of sixty (60) days after receipt of written notice thereof from the other party; (b) at any time, effective as set forth in a written
notice from the other party if Cryogen or CryoCor shall (i) seek the liquidation, reorganization, dissolution or winding-up of itself or the composition or readjustment of its debts (other than pursuant to a merger with an Affiliate), (ii) apply for
or consent to the appointment of, or the 

  

 Schedule 1-1 

 
taking possession by, a receiver, custodian, trustee or liquidator for itself or of all or a substantial part of its assets, (iii) make a general assignment
for the benefit of its creditors, (iv) commence a voluntary case under the Bankruptcy Code, (v) file a petition seeking to take advantage of any other law relating to bankruptcy, insolvency, reorganization, winding-up or composition or readjustment
of debts (other than pursuant to a merger with an Affiliate) or (vi) adopt any resolution of its Board of Directors or shareholders for the purpose of effecting any of the foregoing (other than pursuant to a merger with an Affiliate); or (c) at any
time, effective as set forth in a written notice from the other party, if a proceeding or case shall be commenced without the application or consent of Cryogen or CryoCor as applicable, and such proceeding or case shall continue undismissed, or an
order, judgment or decrees approving or ordering any of the following shall be entered and continued unstayed and in effect, for a period of sixty (60) days from and after the date service of process is effected, seeking (i) Cryogen’s or
CryoCor’s, as applicable, liquidation, reorganization, dissolution or winding-up, or the composition or readjustment of its debts, (ii) the appointment of a trustee, receiver, custodian, liquidator or the like of Cryogen or CryoCor or for all
or any substantial part of its assets or (iii) similar relief in respect of Cryogen or CryoCor under any law relating to bankruptcy, insolvency, reorganization, winding-up or the composition or readjustment of debts. 
  
 “License Agreement” shall mean the License Agreement dated
as of even date herewith, between Cryogen and CryoCor, as amended, modified or supplemented from time to time. 
  
 “Licensed Product(s)” shall mean any and all devices and methods conceived, developed, manufactured, distributed or sold by CryoCor which
utilize all or any portion of the Cryogen Intellectual Property Rights, Cryogen Enhancements (as defined in the License Agreement) or Joint Enhancements (as defined in the License Agreement) for use in performing cardiac or vascular ablation to
treat cardiac arrhythmias. 
  
 “Manufacture”
shall mean the manufacture and assembly of the Licensed Products. 
  
 “Material Obligation” shall mean the material obligations of a party under the License Agreement or this Agreement. 
  
 “Person” shall mean any individual, partnership, corporation, firm, association, unincorporated organization, joint venture, trust or
other entity. 
  
 “Technology” shall mean any
technology that is (a) discovered, developed or otherwise acquired (i) by Cryogen and licensed to CryoCor pursuant to the terms of the License Agreement, (ii) as the result of any development performed by Cryogen on behalf of CryoCor pursuant to
this Agreement or (b) otherwise acquired by or on behalf of CryoCor during the term of the License Agreement or this Agreement. 
  

 Schedule 1-2 

  
 SCHEDULE 2 

 
 COST ACCOUNTING METHODOLOGY 
  
 1. Cryogen will charge CryoCor for time required to support the efforts of CryoCor in certain
functional areas. In these functional areas the Cryogen employee providing support will document time spent supporting CryoCor. The amount charged to CryoCor will be based on the actual time spent at the hourly rate of the individual performing the
services plus a 25% burden rate, in the following functional areas: 
  

	 	•	 	Operations 

  

	 	•	 	Administration 

  

	 	•	 	Regulatory / Clinical 

  

	 	•	 	Quality 

  

	 	•	 	Accounting 

  

	 	•	 	Research and Development 

  

	 	•	 	Legal 

  
 2. Cryogen will charge CryoCor for specific manufacturing overhead tasks based on a rate determined by dividing the spending in an area by a representative activity. This methodology will be used in the following manufacturing overhead
areas: 
  

	 	•	 	Purchasing (allocated based on the purchase order volume) 

  

	 	•	 	Receiving Inspection (allocated based on inspection hours) 

  

	 	•	 	Document Control (allocated based on Engineering Change Notice volume) 

  

	 	•	 	Warehousing (allocated based on purchase order lines received ie: receipts) 

  
 At the end of each calendar year, the comparable actual rate will be calculated (based on the data available subsequent to the last such adjustment) and
compared to the rate used for allocation purposes. The amount allocated subsequent to the time of the last such adjustment will be corrected to reflect the actual rate calculated. Cryogen will refund to CryoCor any over collection or charge an
additional amount to CryoCor based on the adjustment amount calculated. The amount allocated to CryoCor in future periods will be adjusted to reflect the most recent actual rate calculated (unless a more accurate rate is agreed to by both Cryogen
and CryoCor). 
  

 Schedule 2-1 

 3. Cryogen’s real estate and real estate related expenses will be allocated to CryoCor based upon the square footage
of the Cryogen facility occupied by CryoCor employees and activities. Real estate and real estate related expenses shall include the costs of leasing the facility, electricity, natural gas, janitorial, security, facility maintenance and supervision
and trash collection. Cryogen and CryoCor acknowledge and agree that nothing in this Agreement is, or is intended to create, a sublease under or assignment of Cryogen’s facility lease (the “Lease”) to CryoCor. Unless and until CryoCor
enters into a formal written sublease under or assignment of the Lease in compliance with its terms, CryoCor’s sole obligations with respect to Cryogen’s facility shall be as set forth in the first two sentences of this item 3 of Schedule
2. 
  
 4. Copier lease costs, copier supply costs, telephone costs, postage and
general office supplies will be allocated to CryoCor based upon the number of CryoCor headcount occupying the Cryogen facility as a percentage of the total Cryogen and CryoCor employees occupying the Cryogen facility. As CryoCor purchases or
otherwise provides their own copiers, telephones, general office supplies etc., these items will be excluded from this calculation, as applicable. 
  
 5. Cryogen will charge CryoCor for expenses incurred by employees of Cryogen providing support to CryoCor in accordance with item 1 of this Schedule 2, including, without
limitation, reasonable travel expenses incurred by such Cryogen employees; provided, that, such expenses are pre-approved in writing by an authorized representative of CryoCor. 
  

 Schedule 2-2 

  
 SCHEDULE 3 

 
 AGREEMENT OF INITIAL SERVICES TO BE PROVIDED 
  

	1.	The initial requirements for labor to support CryoCor, and agreed to be provided by Cryogen in certain functional areas, will be at least equivalent to the following:

  

										
	 Individual

	  	Minimum Time
Requirements

	 	 	Maximum Time
Requirements

	 	 	Billing
Rate*

	 [...***...]
	  	25	%	 	50	%	 	$	83.61
	 [...***...]
	  	20	%	 	35	%	 	$	87.37
	 [...***...]
	  	10	%	 	25	%	 	$	45.71
	 [...***...]
	  	0	%	 	10	%	 	$	144.49
	 [...***...]
	  	15	%	 	25	%	 	$	85.82
	 [...***...]
	  	0	%	 	10	%	 	$	82.98
	 [...***...]
	  	50	%	 	50	%	 	$	43.16
	 [...***...]
	  	10	%	 	20	%	 	$	49.77
	 [...***...]
	  	15	%	 	35	%	 	$	38.22
	 [...***...]
	  	25	%	 	50	%	 	$	84.56
	 [...***...]
	  	50	%	 	80	%	 	$	56.12
	 [...***...]
	  	35	%	 	70	%	 	$	61.58

   

	*	Based on adjusted salary amounts which have been determined but which have not yet taken effect. Future salary adjustments will result in a proportional adjustment in rate.

  

	2.	Cryogen agrees to provide on CryoCor’s behalf specific manufacturing overhead tasks, as follows: 

  

	 	•	 	Purchasing – Cryogen agrees to provide the purchasing function for all goods and services required by CryoCor for a minimum period of six (6) months. At the option of CryoCor,
the period of purchasing support may be reduced to something less than six (6) months. 

  

	 	•	 	Receiving / inspection – Cryogen agrees to provide the receiving and inspection function for all goods purchased by CryoCor for a minimum period of nine (9) months. At the
option of CryoCor, the period of receiving/inspection support may be reduced to something less than nine (9) months. 

  

	 	•	 	Document Control – Cryogen agrees to provide the Document Control function as required by CryoCor for a minimum period of six (6) months. At the option of CryoCor, the period
of document control support may be reduced to something less than six (6) months. 

  

	 	•	 	Warehousing – Cryogen agrees to provide warehousing for products of CryoCor as required by CryoCor for a minimum of six (6) months. At the option of CryoCor, the period of
warehousing support may be reduced to something less than six (6) months. 

  

					
	 	  	Schedule 3-1	  	* Confidential Treatment Requested

	3.	Cryogen agrees that a minimum of 3,520 square feet will be available in the existing Cryogen facility for CryoCor personnel and activities for a minimum of nine (9) months. At the
option of CryoCor, the minimum square feet requirements and the length of time the facilities are to be made available may be reduced to something less than 3,520 square feet and/or nine (9) months, respectively. 

  

	4.	Cryogen agrees to provide copier and supplies, telephone services, postage and general office supplies for the lesser of a minimum of six (6) months or until CryoCor notifies
Cryogen in writing that CryoCor no longer has a need for any or all of such services and supplies provided by Cryogen. 

  

 Schedule 3-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]